EUVIMEDEUVIMED entdecken
Fallbericht

Real-world use of upadacitinib in refractory giant cell arteritis: a case report

Lisa Wang, Christopher Davidson, Brian Wu, Akihiro Nakamura

Modern Rheumatology Case Reports · 2025

DOI: 10.1093/mrcr/rxaf050 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2025. Verfasst von Lisa Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Rheumatology, Queen's University, Kingston, Ontario, Canada. Hauptthemen laut MEDLINE: Giant Cell Arteritis, Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Giant cell arteritis (GCA) is an autoimmune disease that predominantly affects individuals over 50 years of age by causing inflammation typically in the temporal and cranial arteries. While glucocorticoids like prednisone are the first-line treatment for GCA, glucocorticoid monotherapy is often inadequate for preventing disease flares and is associated with significant side effects when long-term use is required, necessitating the exploration of alternative therapies. Tocilizumab (TCZ) has proven effective as a steroid-sparing agent; however, some patients may respond inadequately or develop adverse events. Treatment with the Janus kinase (JAK) inhibitor upadacitinib (UPA) has recently emerged as a potential alternative therapy for refractory GCA, and its phase III clinical trials successfully demonstrated its efficacy for GCA patients, with or without prior treatment with TCZ. It has also been recently approved by both the European Commission and the U.S. Food and Drug Administration for GCA. However, real-world data on the efficacy of UPA in GCA remain scarce. This case report describes an 82-year-old woman with GCA refractory to both prednisone and TCZ, who reported severe side effects and decreased quality of life from the latter medication. Treatment with UPA resulted in substantial improvements in symptoms, including headaches and fatigue, with minimal negative responses. This outcome demonstrates the potential of UPA as a promising treatment option for GCA patients who are unresponsive or intolerant to current standard therapies. Further real-world studies are warranted to validate UPA’s long-term safety and efficacy in treating GCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Giant Cell ArteritisHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsHumansFemaleAged, 80 and overTreatment OutcomeQuality of LifePrednisoneGlucocorticoids

Stichwörter der Autor:innen

Janus kinase inhibitorsUpadacitinibgiant cell arteritisglucocorticoidstocilizumab

Substanzen

upadacitinibHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsPrednisoneGlucocorticoids

Autor:innen und Institutionen

  • Department of Medicine, Division of Rheumatology, Queen's University, Kingston, Ontario, Canada.
  • Faculty of Health Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada.
  • Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
  • Department of Medicine, Queen's University, Translational Institute of Medicine, Kingston, Ontario, Canada.
  • Rheumatology Clinic, Kingston Health Sciences Centre, Kingston, Ontario, Canada.

Zitieren

APA

Wang, L., Davidson, C., Wu, B., & Nakamura, A. (2025). Real-world use of upadacitinib in refractory giant cell arteritis: a case report. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxaf050

Vancouver

Wang L, Davidson C, Wu B, Nakamura A. Real-world use of upadacitinib in refractory giant cell arteritis: a case report. Modern Rheumatology Case Reports. 2025. doi:10.1093/mrcr/rxaf050

BibTeX
@article{Wang2025,
  author = {Wang, Lisa and Davidson, Christopher and Wu, Brian and Nakamura, Akihiro},
  title = {Real-world use of upadacitinib in refractory giant cell arteritis: a case report},
  journal = {Modern Rheumatology Case Reports},
  year = {2025},
  doi = {10.1093/mrcr/rxaf050}
}
Kostenlos starten →